Metrics to compare | 298380 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship298380PeersSector | |
|---|---|---|---|---|
P/E Ratio | −222.9x | −21.1x | −0.4x | |
PEG Ratio | −3.20 | −0.36 | 0.00 | |
Price/Book | 29.8x | 2.3x | 2.6x | |
Price / LTM Sales | 59.6x | 11.7x | 3.1x | |
Upside (Analyst Target) | 170.6% | 20.6% | 48.8% | |
Fair Value Upside | Unlock | 4.8% | 6.3% | Unlock |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.